Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer

Abstract

Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.

1 - 20 . (canceled) 
     
     
         21 . A method of treating non-metastatic castration-resistant prostate cancer in a male human comprising administering a second-generation anti-androgen to a male human in need of such treatment, wherein the second-generation anti-androgen is administered in combination with a gonadotropin-releasing hormone (GnRH) agonist or antagonist or orchiectomy. 
     
     
         22 . The method of  claim 21 , wherein the non-metastatic castration-resistant prostate cancer is a high risk non-metastatic castration-resistant prostate cancer. 
     
     
         23 . The method of  claim 21 , wherein the second-generation anti-androgen is administered in combination with the GnRH agonist or antagonist. 
     
     
         24 . The method of  claim 21 , wherein the second-generation anti-androgen is administered in combination with the GnRH agonist and the GnRH agonist is leuprolide, buserelin, nafarelin, histrelin, goserelin, or deslorelin. 
     
     
         25 . The method of  claim 21 , wherein the second-generation anti-androgen is administered post-orchiectomy. 
     
     
         26 . The method of  claim 21 , wherein the male human previously received a first-generation anti-androgen, and wherein the first-generation anti-androgen is bicalutamide, flutamide or nilutamide. 
     
     
         27 . The method of  claim 21 , wherein the second-generation anti-androgen is administered daily to the male human. 
     
     
         28 . The method of  claim 21 , wherein the second-generation anti-androgen is administered orally to the male human. 
     
     
         29 . The method of  claim 21 , wherein the second-generation anti-androgen is administered orally to the male human on a continuous daily dosing schedule. 
     
     
         30 . The method of  claim 21 , wherein the second-generation anti-androgen is administered orally to the male human at a dose of about 600 mg. 
     
     
         31 . The method of  claim 21 , wherein the second-generation anti-androgen is administered orally to the male human at a dose of about 600 mg twice a day. 
     
     
         32 . The method of  claim 21 , wherein the second-generation anti-androgen is in a unit dosage form, and wherein the unit dosage form is in the form of a tablet. 
     
     
         33 . A method of treating non-metastatic castration-resistant prostate cancer in a male human consisting essentially of administering a second-generation anti-androgen to a male human in need of such treatment, wherein the second-generation anti-androgen is administered in combination with a gonadotropin-releasing hormone (GnRH) agonist or antagonist or orchiectomy. 
     
     
         34 . The method of  claim 33 , wherein the non-metastatic castration-resistant prostate cancer is a high risk non-metastatic castration-resistant prostate cancer. 
     
     
         35 . The method of  claim 33 , wherein the second-generation anti-androgen is administered in combination with the GnRH agonist or antagonist. 
     
     
         36 . The method of  claim 33 , wherein the second-generation anti-androgen is administered in combination with the GnRH agonist and the GnRH agonist is leuprolide, buserelin, nafarelin, histrelin, goserelin, or deslorelin. 
     
     
         37 . The method of  claim 33 , wherein the second-generation anti-androgen is administered post-orchiectomy. 
     
     
         38 . The method of  claim 33 , wherein the second-generation anti-androgen is administered orally to the male human at a dose of about 600 mg. 
     
     
         39 . The method of  claim 33 , wherein the second-generation anti-androgen is administered orally to the male human at a dose of about 600 mg twice a day.